Nutriband Inc.

7.19
-0.62 (-7.94%)
At close: Feb 10, 2025, 3:59 PM
7.50
4.31%
After-hours Feb 10, 2025, 07:59 PM EST
undefined%
Bid 7.5
Market Cap 79.85M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.71
PE Ratio (ttm) -10.13
Forward PE n/a
Analyst Buy
Ask 7.77
Volume 154,642
Avg. Volume (20D) 192,010
Open 7.72
Previous Close 7.81
Day's Range 7.01 - 7.89
52-Week Range 2.22 - 11.78
Beta undefined

About NTRB

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; e...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2021
Employees 13
Stock Exchange NASDAQ
Ticker Symbol NTRB

Analyst Forecast

According to 1 analyst ratings, the average rating for NTRB stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 80.81% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
3 days ago
+17.09%
Nutriband shares are trading higher after the comp... Unlock content with Pro Subscription
2 weeks ago
+40.88%
Nutriband shares are trading higher after Noble Capital Markets initiated coverage on the stock with an Outperform rating and a $13 price target.
No News article available yet